A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay
Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2015.04.006
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2015
Authors
Publisher
Elsevier BV